Myelodysplastic syndromes, or MDS, are a group of malignancies affecting blood cells. About half of MDS patients go on to develop acute myeloid leukemia (AML), which is the most common leukemia in adults. Together, these diseases affect nearly 16,000 Americans each year.
The incidence of MDS is expected to rise as the population ages. There’s no curative therapy for most patients with MDS. Although the five-year survival rate for AML has vastly improved since the 1970s, it’s still only less than 30%. In addition, half of AML and MDS patients will succumb to complications from their disease or treatment. Clearly, now is the time to find more effective therapies for both of these diseases.
MD Anderson’s AML/MDS Moon Shot will combine the latest treatment technologies and genetic knowledge to identify the most promising new treatments and move them into a clinical setting in a faster, more efficient way.